FDA clears a generic injectable rifampin

The US Food and Drug Administration approved an abbreviated application for injectable rifampin from a single manufacturer. Rifampin is a first-line drug for tuberculosis and a mainstay of several other serious infections.

This is a supply and competition matter rather than clinical news: it adds another source of an established generic, with no change to the drug, its indications or its safety profile. There is nothing here to alter prescribing. It is noted because added manufacturing capacity for first-line antituberculous drugs is welcome against a backdrop of periodic shortages, but the approval itself does not create a new option.

• The FDA approved a generic injectable rifampin from an additional manufacturer.
• Rifampin's indications, dosing and safety are unchanged by this approval.
• The value is added supply and competition for a first-line drug, not a new therapy.
• No prescribing change follows from the approval itself.

Why it matters

Additional manufacturing of first-line antituberculous drugs guards against the shortages that periodically disrupt treatment.

Don't overread it

This is an administrative generic approval, not a new drug, a new indication, or a safety finding.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.